Literature DB >> 28912267

Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.

Thomas B Huffaker1, Soh-Hyun Lee1, William W Tang1, Jared A Wallace1, Margaret Alexander1, Marah C Runtsch1, Dane K Larsen1, Jacob Thompson1, Andrew G Ramstead1, Warren P Voth1, Ruozhen Hu1, June L Round1, Matthew A Williams1, Ryan M O'Connell2.   

Abstract

MicroRNA-155 (miR-155) regulates antitumor immune responses. However, its specific functions within distinct immune cell types have not been delineated in conditional KO mouse models. In this study, we investigated the role of miR-155 specifically within T cells during the immune response to syngeneic tumors. We found that miR-155 expression within T cells is required to limit syngeneic tumor growth and promote IFNγ production by T cells within the tumor microenvironment. Consequently, we found that miR-155 expression by T cells is necessary for proper tumor-associated macrophage expression of IFNγ-inducible genes. We also found that immune checkpoint-blocking (ICB) antibodies against programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) restored antitumor immunity in miR-155 T cell-conditional KO mice. We noted that these ICB antibodies rescued the levels of IFNγ-expressing T cells, expression of multiple activation and effector genes expressed by tumor-infiltrating CD8+ and CD4+ T cells, and tumor-associated macrophage activation. Moreover, the ICB approach partially restored expression of several derepressed miR-155 targets in tumor-infiltrating, miR-155-deficient CD8+ T cells, suggesting that miR-155 and ICB regulate overlapping pathways to promote antitumor immunity. Taken together, our findings highlight the multifaceted role of miR-155 in T cells, in which it promotes antitumor immunity. These results suggest that the augmentation of miR-155 expression could be used to improve anticancer immunotherapies.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  T cell; cellular immune response; leukocyte; miR-155; microRNA (miRNA); tumor immunology; tumor microenvironment

Mesh:

Substances:

Year:  2017        PMID: 28912267      PMCID: PMC5682963          DOI: 10.1074/jbc.M117.808121

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  miR-155 promotes T follicular helper cell accumulation during chronic, low-grade inflammation.

Authors:  Ruozhen Hu; Dominique A Kagele; Thomas B Huffaker; Marah C Runtsch; Margaret Alexander; Jin Liu; Erin Bake; Wei Su; Matthew A Williams; Dinesh S Rao; Thomas Möller; Gwenn A Garden; June L Round; Ryan M O'Connell
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

2.  Hematopoietic stem cells expressing the myeloid lysozyme gene retain long-term, multilineage repopulation potential.

Authors:  Min Ye; Hiromi Iwasaki; Catherine V Laiosa; Matthias Stadtfeld; Huafeng Xie; Susanne Heck; Bjorn Clausen; Koichi Akashi; Thomas Graf
Journal:  Immunity       Date:  2003-11       Impact factor: 31.745

Review 3.  The widespread regulation of microRNA biogenesis, function and decay.

Authors:  Jacek Krol; Inga Loedige; Witold Filipowicz
Journal:  Nat Rev Genet       Date:  2010-07-27       Impact factor: 53.242

4.  MicroRNA-155 regulates inflammatory cytokine production in tumor-associated macrophages via targeting C/EBPbeta.

Authors:  Min He; Zhenqun Xu; Tong Ding; Dong-Ming Kuang; Limin Zheng
Journal:  Cell Mol Immunol       Date:  2009-10       Impact factor: 11.530

Review 5.  MicroRNAs as regulatory elements in immune system logic.

Authors:  Arnav Mehta; David Baltimore
Journal:  Nat Rev Immunol       Date:  2016-04-28       Impact factor: 53.106

Review 6.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

7.  miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines.

Authors:  Yun Ji; Claudia Wrzesinski; Zhiya Yu; Jinhui Hu; Sanjivan Gautam; Nga V Hawk; William G Telford; Douglas C Palmer; Zulmarie Franco; Madhusudhanan Sukumar; Rahul Roychoudhuri; David Clever; Christopher A Klebanoff; Charles D Surh; Thomas A Waldmann; Nicholas P Restifo; Luca Gattinoni
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-29       Impact factor: 11.205

8.  Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism.

Authors:  Siqi Chen; Long Wang; Jie Fan; Cong Ye; Donye Dominguez; Yi Zhang; Tyler J Curiel; Deyu Fang; Timothy M Kuzel; Bin Zhang
Journal:  Cancer Res       Date:  2014-12-10       Impact factor: 12.701

9.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

10.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

View more
  32 in total

1.  T Cell-Expressed microRNA-155 Reduces Lifespan in a Mouse Model of Age-Related Chronic Inflammation.

Authors:  H Atakan Ekiz; Andrew G Ramstead; Soh-Hyun Lee; Morgan C Nelson; Kaylyn M Bauer; Jared A Wallace; Ruozhen Hu; June L Round; Jared Rutter; Micah J Drummond; Dinesh S Rao; Ryan M O'Connell
Journal:  J Immunol       Date:  2020-03-11       Impact factor: 5.422

2.  MicroRNA-155 coordinates the immunological landscape within murine melanoma and correlates with immunity in human cancers.

Authors:  H Atakan Ekiz; Thomas B Huffaker; Allie H Grossmann; W Zac Stephens; Matthew A Williams; June L Round; Ryan M O'Connell
Journal:  JCI Insight       Date:  2019-03-21

3.  Identification and characterization of novel CD274 (PD-L1) regulating microRNAs and their functional relevance in melanoma.

Authors:  Christoforos K Vaxevanis; Michael Friedrich; Sandy Uta Tretbar; Diana Handke; Yuan Wang; Juliane Blümke; Reinhard Dummer; Chiara Massa; Barbara Seliger
Journal:  Clin Transl Med       Date:  2022-07

4.  The polysaccharide of Atractylodes macrocephala koidz (PAMK) alleviates cyclophosphamide-mediated immunosuppression in geese, possibly through novel_mir2 targeting of CTLA4 to upregulate the TCR-NFAT pathway.

Authors:  Wanyan Li; Danning Xu; Bingxin Li; Nan Cao; Sixuan Guo; Qingyan Jiang; Yunbo Tian
Journal:  RSC Adv       Date:  2018-07-27       Impact factor: 4.036

5.  Effects of allergic stimulation and glucocorticoids on miR-155 in CD4+ T-cells.

Authors:  Elizabeth Daniel; Alanna Roff; Man-Hsun Hsu; Ronaldo Panganiban; Kristin Lambert; Faoud Ishmael
Journal:  Am J Clin Exp Immunol       Date:  2018-08-20

Review 6.  Non-coding RNAs in CD8 T cell biology.

Authors:  Alexandria C Wells; Elena L Pobezinskaya; Leonid A Pobezinsky
Journal:  Mol Immunol       Date:  2020-02-18       Impact factor: 4.407

Review 7.  microRNA-based diagnostic and therapeutic applications in cancer medicine.

Authors:  Lorenzo F Sempere; Asfar S Azmi; Anna Moore
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-05-17       Impact factor: 9.957

8.  A Stat1 bound enhancer promotes Nampt expression and function within tumor associated macrophages.

Authors:  Thomas B Huffaker; H Atakan Ekiz; Cindy Barba; Soh-Hyun Lee; Marah C Runtsch; Morgan C Nelson; Kaylyn M Bauer; William W Tang; Timothy L Mosbruger; James E Cox; June L Round; Warren P Voth; Ryan M O'Connell
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

9.  Key questions about the checkpoint blockade-are microRNAs an answer?

Authors:  Mihnea Dragomir; Baoqing Chen; Xiao Fu; George A Calin
Journal:  Cancer Biol Med       Date:  2018-05       Impact factor: 4.248

Review 10.  microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy.

Authors:  Elena Daveri; Elisabetta Vergani; Eriomina Shahaj; Laura Bergamaschi; Stefano La Magra; Michela Dosi; Chiara Castelli; Monica Rodolfo; Licia Rivoltini; Viviana Vallacchi; Veronica Huber
Journal:  Front Immunol       Date:  2020-07-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.